Immuron Limited (ASX: IMC)
The global immunotherapy drugs market is projected to double over the next few years – from US$100BN right now, swelling to US$200BN by 2021.
That’s a large addressable market for a company with cutting edge technology and products that could change the treatment landscape in this field.
This company in particular is tackling fatty liver disease, which is seeing spiralling rates of incidence as obesity and diabetes cases continue to grow.
Via a long term gut health technology platform, this ASX stock has a pipeline of clinical studies ahead. The current focus is on a Phase II clinical trials, which is already underway.
Given the frenzied activity of Big Pharma in this space, it’s no wonder this ASX stock is gearing up for a NASDAQ listing – the US is where the big bucks are in this space.
This ASX stock already has a proof of concept, revenue generating drug derived for its gut health technology platform – a drug that treats ‘Bali belly’ or ‘travellers’ diarrhoea’ quickly and effectively.
Aside from its over the counter drug Travelan, this company is looking to produce orally stable therapies for a range of conditions including diabetes, arthritis, IBS and infections.
With considerable near-term news flow regarding Interim results and then final results of its Phase II clinical trials, any positive results could garner investors’ attention, as well as catch the eye of Big Pharma.
The information on this page should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
So with a revenue generating product already on market, a pipeline of products to come and a technology platform that ties it all together, this company is looking squarely down the barrel of a major charge at this highly lucrative sector of the health market.